Saturday, June 19, 2021
Home Tags Psychedelic medicine

Psychedelic medicine Related News

GCI Summit: exploring cannabis and psychedelics

GCI Summit: exploring cannabis and psychedelics

This week, the GCI Summit gives global leaders the opportunity to network with the best minds in cannabis and psychedelics. Taking place from 8 to...
Health Europa Quarterly Issue 17

Health Europa Quarterly Issue 17

Welcome to the 17th issue of Health Europa Quarterly, which focuses on the fast-growing worlds of infection prevention and control and digital health technology;...
mescaline

XPhyto: Is mescaline the next big mood-modifying medicine?

Mescaline has the potential to be the next frontier in the psychedelics renaissance and represents an unprecedented opportunity to innovate a notable advancement in...

XPhyto Therapeutics diversifies into psychedelics with new labs

XPhyto Therapeutics is diversifying into psychedelic medicines by launching XPhyto Laboratories. Among the leading contenders in the race to pioneer new blockbuster psychiatric drugs is...
Results from world’s first MDMA alcohol use disorder trial

Results from world’s first MDMA alcohol use disorder trial

The world’s first trial investigating the role of MDMA therapy for the treatment of alcohol use disorder has shown positive results. Awakn Life Sciences' Bristol...
World’s first research and cultivation facility for psychedelic mushrooms

World’s first research and cultivation facility for psychedelic mushrooms

A new partnership will see the world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics. Field Trip Health,...
The case for mass producing psychedelic pharmaceuticals

The case for mass producing psychedelic pharmaceuticals

In this article, financial journalist Marc Davis discusses the mass production of psychedelic pharmaceuticals and the steep educational curve facing medical science. Medical science is...
Agreement for synthesis of pharmaceutical grade psychedelic compounds

Agreement for synthesis of pharmaceutical grade psychedelic compounds

A new agreement has been struck  to enable the synthesis of pharmaceutical grade psychedelic compounds in a bid to ensure there is not a...
UK’s first investment fund dedicated to psychedelic healthcare

UK’s first investment fund dedicated to psychedelic healthcare

In a first for the UK, an investment fund dedicated to psychedelic healthcare has been launched. The new fund comes as recent rigorous clinical trials...
Clinical trial explores psychedelic treatments for PTSD in veterans

Clinical trial explores psychedelic treatments for PTSD in veterans

A company exploring the efficacy of psychedelic treatments for PTSD in veterans has announced the international expansion of its Phase 2A clinical trials. The Mydecine...
Combatting resistant depression with DMT and digital therapy

Combatting resistant depression with DMT and digital therapy

A wellbeing company is developing novel formulations of dimethyltryptamine (DMT) to help combat treatment resistant depression in combination with digital psychotherapy. Nearly 264 million people live...
Psychedelics association to bridge medical establishment and industry gap

Psychedelics association to bridge medical establishment and industry gap

Leaders in the field of psychedelic medicine have joined forces to create the global Psychedelic Medicine Association (PMA), which aims to bridge the gap...
Ketamine therapy insights from experts in the field

Ketamine therapy insights from experts in the field

A Molecular Masterclass conference delved into the benefits, research, and policy surrounding ketamine therapy. The masterclass explored ketamine at the intersection of clinical care, research,...
The Ketamine Conference: a molecular masterclass

The Ketamine Conference: A Molecular Masterclass

The Ketamine Conference: A Molecular Masterclass is set to take place today, featuring a host of experts in the delivery of ketamine therapy for...
Drug policy reform group urges Home Office to reschedule psilocybin

Drug policy reform group urges Home Office to reschedule psilocybin

The Conservative Drug Policy Reform Group (CDPRG) has published a new report with the Adam Smith Institute outlining the potential medical benefits of psilocybin...
Medical Psychedelics Working Group to campaign for drug rescheduling 

Medical Psychedelics Working Group to campaign for drug rescheduling 

The Medical Psychedelics Working Group has now been launched in the UK to campaign for the rescheduling of all psychedelic drugs for research and...
Could ibogaine offer a revolutionary long-term solution to addiction?

Could ibogaine offer a revolutionary long-term solution to addiction?

Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential as a long-term solution to addiction. ATAI Life Sciences...
Could arketamine provide breakthrough therapy for depression?

Could arketamine be a breakthrough therapy for depression?

Clinical trials are being carried out to test the efficacy of arketamine as therapy for depression, with the aim of offering an alternative to...
Cannabis and psychedelics: gatherings to accelerate plant-based medicine

Cannabis and psychedelics: gatherings to accelerate plant-based medicine

The world's leading cannabis and psychedelic medicines scientists and researchers, investors, industry leaders and opinion makers will gather in Tel Aviv next month for...
MDMA-assisted psychotherapy for PTSD approved by FDA

MDMA-assisted psychotherapy for PTSD approved by FDA

A new programme will enrol 50 PTSD patients for MDMA-assisted psychotherapy following FDA approval. The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) was recently granted...

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest